Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
Alexander Drilon(Memorial Sloan Kettering Cancer Center), Vivek Subbiah(Sarah Cannon), Elizabeth Olek(Memorial Sloan Kettering Cancer Center), Filippo de Braud(University of Milan), S. Michael Rothenberg(Pfizer (United States)), Jared Weiss(University of North Carolina at Chapel Hill), Benjamin Besse(Institut Gustave Roussy), Grace K. Dy(Roswell Park Comprehensive Cancer Center), Philippe A. Cassier(Centre Léon Bérard), Binoj C. Nair(Eli Lilly (United States)), Keunchil Park(The University of Texas MD Anderson Cancer Center), Herbert H. Loong(Memorial Sloan Kettering Cancer Center), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Nir Peled(Shaare Zedek Medical Center), Jyoti D. Patel(Memorial Sloan Kettering Cancer Center), Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Manisha H. Shah(Pakistan Institute of Medical Sciences), Luxi Yang(Memorial Sloan Kettering Cancer Center), Lyudmila Bazhenova(Memorial Sloan Kettering Cancer Center), Kōichi Goto(National Cancer Center Hospital East), Geoffrey R. Oxnard(Foundation Medicine (United States)), Benjamin Solomon(Peter MacCallum Cancer Centre), Melissa L. Johnson(Tennessee Oncology), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Elena Garralda(Memorial Sloan Kettering Cancer Center), Yu-Jung Kim(Memorial Sloan Kettering Cancer Center), Byoung Chul Cho(Yonsei University), Vamsidhar Velcheti(Cleveland Clinic), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Xin Huang(Lineage Cell Therapeutics (United States)), Tomohiro Sakamoto(Memorial Sloan Kettering Cancer Center), Makoto Nishio(Japanese Foundation For Cancer Research), Kevin Ebata(Memorial Sloan Kettering Cancer Center), Ezra Y. Rosen(Kettering University), Justin F. Gainor(Harvard University), Fabrice Barlési(Hôpital Nord), Yuichiro Ohe(National Cancer Center), Michele Nguyen(Memorial Sloan Kettering Cancer Center), Daniel Shao-Weng Tan(Memorial Sloan Kettering Cancer Center), Edward Y. Zhu(Memorial Sloan Kettering Cancer Center), Nathan A. Pennell(Cleveland Clinic), Jürgen Wolf(University of Cologne), Kadoaki Ohashi(Okayama University Hospital)
Cited by 835
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k